The effect of L-carnitine in the treatment of anemia

L-carnitine effects on anemia improvement in patients undergoing hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180921041080N1

Enrollment

100

Registered

2018-11-30

Start date

2018-11-22

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal Disease. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: Patients in the intervention group will treated for 12 weeks with a single daily dose of L-carnitine tablets containing one gram of L-carnitine tartrate produced by

Eligibility

Sex/Gender

All

Age

20 Years to 74 Years

Inclusion criteria

Inclusion criteria: Patients undergoing hemodialysis Having anemia Hemodialysis more than one year Age more than 20 years

Exclusion criteria

Exclusion criteria: Having infectious, hepatic, and cancer diseases Previous use of L-carnitine supplement Use of corticosteroids Narcotic drugs, alcohol, and cigarette consumption

Design outcomes

Primary

Measure	Time frame
Anemia. Timepoint: Mean serum hemoglobin, ferritin and iron levels are measured at the beginning and three months after the start of treatment. Method of measurement: Blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnvar Mohamadi Baneh

Kurdistan University of Medical Sciences

dr.khorshidy@gmail.com+98 87 3328 7100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026